Connect Biopharma Holdings (CNTB) Receivables - Net (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted Receivables - Net of $13000.0 for Q4 2025, down 23.53% sequentially from $17000.0 in Q3 2025.

Connect Biopharma Holdings (CNTB) Receivables - Net (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported Receivables - Net for 2 years, with the latest figure at $13000.0 in Q4 2025.

Quarterly Receivables - Net changed N/A year-over-year to $13000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13000.0 (changed N/A YoY) and the FY2025 annual result came in at $13000.0, down 98.35% from the prior year.
Receivables - Net declined to $13000.0 in Q4 2025 per CNTB's latest filing, from $17000.0 in the prior quarter.
Over five years, Receivables - Net peaked at $3.6 million in Q2 2024 and troughed at $8000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.09 Bn	131.23 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.66 Bn	77.66 Bn	3.93 Bn
3	Argenx Se	64.86 Bn	59.67 Bn	1.37 Bn
4	Moderna	58.07 Bn	52.93 Bn	52.00 Mn
5	BeOne Medicines	41.87 Bn	36.77 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.45 Bn	28.15 Bn	992.69 Mn
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn
9	Royalty Pharma	27.28 Bn	26.45 Bn	-
10	Connect Biopharma Holdings	148.09 Mn	148.09 Mn	-

Download Data